Clinical Trial Update: A Study of Norepinephrine in Patients With Congenital Insensitivity to Pain and Anhidrosis [Phase 2]

View source ↗

Summary

The Phase 2 trial of norepinephrine for hereditary sensory and autonomic neuropathy type IV (congenital insensitivity to pain with anhidrosis) has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Sensory and Autonomic Neuropathy Type Iv

Drugs mentioned

• NOREPINEPHRINE (NOREPINEPHRINE BITARTRATE)

Snippet

Sponsor: NYU Langone Health | Conditions: HSAN Type IV | Phase 2 | Status: WITHDRAWN